SCHEMBL23798668

SCHEMBL23798668

CC(C)(C)OC(=O)/N=C1\CC[C@H](C(=O)O)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.36
▸ GABRP O00591 2/20 0.35
▸ GABRD O14764 2/20 0.35
▸ GABRA1 P14867 2/20 0.35
▸ GABRB1 P18505 2/20 0.35
▸ GABRG2 P18507 2/20 0.35
▸ GABRB3 P28472 2/20 0.35
▸ GABRA5 P31644 2/20 0.35
▸ GABRA3 P34903 2/20 0.35
▸ GABRA2 P47869 2/20 0.35
▸ GABRB2 P47870 2/20 0.35
▸ GABRA4 P48169 2/20 0.35
▸ GABRE P78334 2/20 0.35
▸ GABRA6 Q16445 2/20 0.35
▸ GABRG1 Q8N1C3 2/20 0.35
▸ GABRG3 Q99928 2/20 0.35
▸ GABRQ Q9UN88 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19174501 0.72 KDM4E (0.40) KMT2AALDH1A1POLB
SCHEMBL14532156 0.72 CHRM2 (0.37) KMT2AALDH1A1
SCHEMBL10713526 0.71 GABRP (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL6562501 0.69 BTK (0.39) BTKKMT2AHSD17B10GABRPGABRD
SCHEMBL20068385 0.69 BTK (0.39) BTKKMT2AHSD17B10GABRPGABRD
SCHEMBL708881 0.68 GABRP (0.41) KMT2AHSD17B10GABRPGABRDGABRA1
SCHEMBL20068383 0.68 BTK (0.38) BTKKMT2AHSD17B10SMN1; SMN2LMNA
SCHEMBL22310390 0.68 BTK (0.38) BTKKMT2AHSD17B10POLBSMN1; SMN2
SCHEMBL26964726 0.68 BTK (0.38) BTKKMT2AHSD17B10GABRPGABRD
SCHEMBL1072603 0.67 HRH3 (0.46) BTKKMT2AALDH1A1HSD17B10GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526207-B1 HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. HEPTARES THERAPEUTICS LTD (GB) 2021-09-08 — — EP disclosed
Send feedback